Supernus director nets 18,787-share stock sale

Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales.

Rhea-AI Filing Summary

Supernus Pharmaceuticals director Georges Gemayel reported an option exercise and related stock sales. On March 6, 2026, he exercised a director stock option for 7,905 shares, receiving common stock at an exercise price of $0.00 per share, and held 36,064 shares afterward.

He then sold 10,000 shares of common stock on March 5, 2026 at a weighted average price of about $53.71, and a further 8,787 shares on March 6, 2026 at about $53.00, in open-market transactions. After these sales, he directly owned 27,277 shares of Supernus common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider GEMAYEL GEORGES

Role Director

Sold 18,787 shs ($1.00M)

Approx. gross sale proceeds $1.00M

Approx. exercise cost $200K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (Right to Buy)	7,905	$0.00	$0.00
Exercise	Common Stock	7,905	$25.30	$200K
Sale	Common Stock	8,787	$53.00	$466K
Sale	Common Stock	10,000	$53.71	$537K

Holdings After Transaction: Director Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 27,277 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Georges Gemayel report for SUPN?

Georges Gemayel reported exercising a director stock option for 7,905 shares and then selling 18,787 shares of Supernus common stock in open-market transactions. Following these trades, he directly owned 27,277 Supernus Pharmaceuticals shares.

How many Supernus (SUPN) shares did the director sell and at what prices?

The director sold a total of 18,787 Supernus shares. He sold 10,000 shares at a weighted average price of about $53.71 and 8,787 shares at about $53.00, with individual trades ranging between $53.00 and $54.15.

What stock option exercise did the Supernus (SUPN) director report?

He exercised a director stock option for 7,905 shares of Supernus common stock on March 6, 2026. The option carried a reported exercise price of $0.00 per share, and the resulting shares were held directly before subsequent sales.

How many Supernus (SUPN) shares does Georges Gemayel own after these transactions?

After the reported option exercise and stock sales, Georges Gemayel directly owns 27,277 shares of Supernus common stock. This reflects his updated direct beneficial ownership following the exercise of 7,905 options and sales totaling 18,787 shares.

Were the Supernus (SUPN) director’s share sales open-market transactions?

Yes. The Form 4 describes both stock sales as open-market or private transactions coded as “S.” The prices were reported as weighted averages, with underlying trades executed in multiple transactions within specified price ranges between $53.00 and $54.15.

Did the Supernus (SUPN) director both acquire and sell shares in this filing?

Yes. He acquired 7,905 shares through exercising a director stock option and sold 18,787 shares in open-market transactions. Overall, the transactions result in a net reduction of his holdings but leave him with 27,277 directly owned shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEMAYEL GEORGES

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S		10,000	D	$53.71(1)	28,159	D
Common Stock	03/06/2026		M		7,905	A	$25.3	36,064	D
Common Stock	03/06/2026		S		8,787	D	$53(2)	27,277	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$25.3	03/06/2026		M			7,905	02/24/2018	02/24/2027	Common Stock	7,905	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.50 to $54.15. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.03. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.